# Viatris Inc: financial statements, quarterly

VTRS · Nasdaq · CIK 1792044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vtrs.md) · [Financials](/companies/vtrs/financials.md) · [Filings](/companies/vtrs/filings.md) · [Insiders](/companies/vtrs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vtrs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,934](/filings/0001792044-24-000033.md) | [3,826 d](/filings/0001792044-26-000013.md) | [3,654](/filings/0001792044-25-000018.md) | [3,786](/filings/0001792044-25-000033.md) | [3,738](/filings/0001792044-25-000046.md) | [3,515 d](/filings/0001792044-26-000013.md) | [3,243](/filings/0001792044-26-000029.md) | [3,569](/filings/0001792044-26-000041.md) | [3,748](/filings/0001792044-25-000046.md) | [3,691 d](/filings/0001792044-26-000013.md) | [3,510](/filings/0001792044-26-000029.md) | [3,746](/filings/0001792044-26-000041.md) |
| Cost of revenue | $m | [2,251](/filings/0001792044-24-000033.md) | [2,241 d](/filings/0001792044-26-000013.md) | [2,159](/filings/0001792044-25-000018.md) | [2,351](/filings/0001792044-25-000033.md) | [2,292](/filings/0001792044-25-000046.md) | [2,313 d](/filings/0001792044-26-000013.md) | [2,093](/filings/0001792044-26-000029.md) | [2,249](/filings/0001792044-26-000041.md) | [2,388](/filings/0001792044-25-000046.md) | [2,556 d](/filings/0001792044-26-000013.md) | [2,360](/filings/0001792044-26-000029.md) | [2,300](/filings/0001792044-26-000041.md) |
| Gross profit | $m | [1,691](/filings/0001792044-24-000033.md) | [1,597 d](/filings/0001792044-26-000013.md) | [1,504](/filings/0001792044-25-000018.md) | [1,445](/filings/0001792044-25-000033.md) | [1,459](/filings/0001792044-25-000046.md) | [1,215 d](/filings/0001792044-26-000013.md) | [1,161](/filings/0001792044-26-000029.md) | [1,333](/filings/0001792044-26-000041.md) | [1,372](/filings/0001792044-25-000046.md) | [1,148 d](/filings/0001792044-26-000013.md) | [1,157](/filings/0001792044-26-000029.md) | [1,457](/filings/0001792044-26-000041.md) |
| Research and development | $m | [211](/filings/0001792044-24-000033.md) | not reported | [200](/filings/0001792044-25-000018.md) | [204](/filings/0001792044-25-000033.md) | [198](/filings/0001792044-25-000046.md) | not reported | [222](/filings/0001792044-26-000029.md) | [219](/filings/0001792044-26-000041.md) | [250](/filings/0001792044-25-000046.md) | not reported | [249](/filings/0001792044-26-000029.md) | [248](/filings/0001792044-26-000041.md) |
| Selling, general and administrative | $m | [1,054](/filings/0001792044-24-000033.md) | [1,026 d](/filings/0001792044-26-000013.md) | [1,018](/filings/0001792044-25-000018.md) | [1,037](/filings/0001792044-25-000033.md) | [1,003](/filings/0001792044-25-000046.md) | [1,047 d](/filings/0001792044-26-000013.md) | [948](/filings/0001792044-26-000029.md) | [929](/filings/0001792044-26-000041.md) | [887](/filings/0001792044-25-000046.md) | [1,031 d](/filings/0001792044-26-000013.md) | [929](/filings/0001792044-26-000029.md) | [1,135](/filings/0001792044-26-000041.md) |
| Operating income | $m | [452](/filings/0001792044-24-000033.md) | [(455) d](/filings/0001792044-26-000013.md) | [204](/filings/0001792044-25-000018.md) | [(240)](/filings/0001792044-25-000033.md) | [226](/filings/0001792044-25-000046.md) | [(180) d](/filings/0001792044-26-000013.md) | [(2,882)](/filings/0001792044-26-000029.md) | [233](/filings/0001792044-26-000041.md) | [179](/filings/0001792044-25-000046.md) | [(193) d](/filings/0001792044-26-000013.md) | [(79.7)](/filings/0001792044-26-000029.md) | [6.3](/filings/0001792044-26-000041.md) |
| Interest expense | $m | [142](/filings/0001792044-24-000033.md) | [141 d](/filings/0001792044-26-000013.md) | [138](/filings/0001792044-25-000018.md) | [146](/filings/0001792044-25-000033.md) | [146](/filings/0001792044-25-000046.md) | [120 d](/filings/0001792044-26-000013.md) | [116](/filings/0001792044-26-000029.md) | [117](/filings/0001792044-26-000041.md) | [120](/filings/0001792044-25-000046.md) | [120 d](/filings/0001792044-26-000013.md) | [120](/filings/0001792044-26-000029.md) | [121](/filings/0001792044-26-000041.md) |
| Income tax | $m | [70.6](/filings/0001792044-24-000033.md) | [(89.4) d](/filings/0001792044-26-000013.md) | [90.7](/filings/0001792044-25-000018.md) | [(65.4)](/filings/0001792044-25-000033.md) | [(4.3)](/filings/0001792044-25-000046.md) | [(10.0) d](/filings/0001792044-26-000013.md) | [(55.0)](/filings/0001792044-26-000029.md) | [(213)](/filings/0001792044-26-000041.md) | [120](/filings/0001792044-25-000046.md) | [(2.9) d](/filings/0001792044-26-000013.md) | [(424)](/filings/0001792044-26-000029.md) | [54.8](/filings/0001792044-26-000041.md) |
| Net income | $m | [332](/filings/0001792044-24-000033.md) | [(766) d](/filings/0001792044-26-000013.md) | [114](/filings/0001792044-25-000018.md) | [(326)](/filings/0001792044-25-000033.md) | [94.8](/filings/0001792044-25-000046.md) | [(517) d](/filings/0001792044-26-000013.md) | [(3,042)](/filings/0001792044-26-000029.md) | [(4.6)](/filings/0001792044-26-000041.md) | [(128)](/filings/0001792044-25-000046.md) | [(340) d](/filings/0001792044-26-000013.md) | [176](/filings/0001792044-26-000029.md) | [(119)](/filings/0001792044-26-000041.md) |
| Diluted EPS | $ per share | [0.27](/filings/0001792044-24-000033.md) | not reported | [0.09](/filings/0001792044-25-000018.md) | [(0.27)](/filings/0001792044-25-000033.md) | [0.08](/filings/0001792044-25-000046.md) | not reported | [(2.55)](/filings/0001792044-26-000029.md) | [0.00](/filings/0001792044-26-000041.md) | [(0.11)](/filings/0001792044-25-000046.md) | not reported | [0.15](/filings/0001792044-26-000029.md) | [(0.10)](/filings/0001792044-26-000041.md) |
| Basic EPS | $ per share | [0.28](/filings/0001792044-24-000033.md) | not reported | [0.10](/filings/0001792044-25-000018.md) | [(0.27)](/filings/0001792044-25-000033.md) | [0.08](/filings/0001792044-25-000046.md) | not reported | [(2.55)](/filings/0001792044-26-000029.md) | [0.00](/filings/0001792044-26-000041.md) | [(0.11)](/filings/0001792044-25-000046.md) | not reported | [0.15](/filings/0001792044-26-000029.md) | [(0.10)](/filings/0001792044-26-000041.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.3](/filings/0001792044-24-000033.md) | [1.0](/filings/0001792044-26-000013.md) | [1.0](/filings/0001792044-25-000018.md) | [0.9](/filings/0001792044-25-000033.md) | [1.9](/filings/0001792044-25-000046.md) | [0.7](/filings/0001792044-26-000013.md) | [0.8](/filings/0001792044-26-000029.md) | [0.6](/filings/0001792044-26-000041.md) | [1.0](/filings/0001792044-25-000046.md) | [1.3](/filings/0001792044-26-000041.md) | [1.8](/filings/0001792044-26-000029.md) | [0.9](/filings/0001792044-26-000041.md) |
| Current assets | $bn | [10.9](/filings/0001792044-23-000033.md) | [13.0](/filings/0001792044-25-000008.md) | [12.9](/filings/0001792044-24-000017.md) | [11.8](/filings/0001792044-24-000025.md) | [11.3](/filings/0001792044-24-000033.md) | [9.5](/filings/0001792044-26-000013.md) | [9.6](/filings/0001792044-25-000018.md) | [9.8](/filings/0001792044-25-000033.md) | [10.0](/filings/0001792044-25-000046.md) | [9.8](/filings/0001792044-26-000041.md) | [10.9](/filings/0001792044-26-000029.md) | [10.1](/filings/0001792044-26-000041.md) |
| Total assets | $bn | [48.7](/filings/0001792044-23-000033.md) | [47.7](/filings/0001792044-25-000008.md) | [47.3](/filings/0001792044-24-000017.md) | [45.3](/filings/0001792044-24-000025.md) | [44.8](/filings/0001792044-24-000033.md) | [41.5](/filings/0001792044-26-000013.md) | [38.5](/filings/0001792044-25-000018.md) | [38.4](/filings/0001792044-25-000033.md) | [37.9](/filings/0001792044-25-000046.md) | [37.2](/filings/0001792044-26-000041.md) | [36.8](/filings/0001792044-26-000029.md) | [35.0](/filings/0001792044-26-000041.md) |
| Current liabilities | $bn | [6.8](/filings/0001792044-23-000033.md) | [7.8](/filings/0001792044-25-000008.md) | [7.8](/filings/0001792044-24-000017.md) | [7.7](/filings/0001792044-24-000025.md) | [7.5](/filings/0001792044-24-000033.md) | [5.8](/filings/0001792044-26-000013.md) | [5.7](/filings/0001792044-25-000018.md) | [7.1](/filings/0001792044-25-000033.md) | [7.4](/filings/0001792044-25-000046.md) | [7.1](/filings/0001792044-26-000041.md) | [6.8](/filings/0001792044-26-000029.md) | [6.3](/filings/0001792044-26-000041.md) |
| Total liabilities | $bn | [27.9](/filings/0001792044-23-000033.md) | [27.2](/filings/0001792044-25-000008.md) | [27.3](/filings/0001792044-24-000017.md) | [25.8](/filings/0001792044-24-000025.md) | [25.0](/filings/0001792044-24-000033.md) | [22.9](/filings/0001792044-26-000013.md) | [22.8](/filings/0001792044-25-000018.md) | [22.8](/filings/0001792044-25-000033.md) | [22.7](/filings/0001792044-25-000046.md) | [22.5](/filings/0001792044-26-000041.md) | [22.2](/filings/0001792044-26-000029.md) | [20.8](/filings/0001792044-26-000041.md) |
| Long-term debt | $bn | [17.1](/filings/0001792044-23-000033.md) | [16.2](/filings/0001792044-25-000008.md) | [16.1](/filings/0001792044-24-000017.md) | [14.7](/filings/0001792044-24-000025.md) | [14.3](/filings/0001792044-24-000033.md) | [14.0](/filings/0001792044-26-000013.md) | [14.2](/filings/0001792044-25-000018.md) | [12.8](/filings/0001792044-25-000033.md) | [12.5](/filings/0001792044-25-000046.md) | [12.5](/filings/0001792044-26-000041.md) | [12.4](/filings/0001792044-26-000029.md) | [11.6](/filings/0001792044-26-000041.md) |
| Current portion of debt | $bn | [1.3](/filings/0001792044-23-000033.md) | [1.9](/filings/0001792044-25-000008.md) | [1.9](/filings/0001792044-24-000017.md) | [2.4](/filings/0001792044-24-000025.md) | [1.4](/filings/0001792044-24-000033.md) | [0.0](/filings/0001792044-26-000013.md) | [0.0](/filings/0001792044-25-000018.md) | [1.7](/filings/0001792044-25-000033.md) | [2.0](/filings/0001792044-25-000046.md) | [1.9](/filings/0001792044-26-000041.md) | [1.9](/filings/0001792044-26-000029.md) | [1.7](/filings/0001792044-26-000041.md) |
| Short-term borrowings | $bn | [0.0](/filings/0001792044-23-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [20.9](/filings/0001792044-24-000033.md) | [20.5](/filings/0001792044-26-000013.md) | [20.0](/filings/0001792044-25-000033.md) | [19.5](/filings/0001792044-25-000046.md) | [19.8](/filings/0001792044-25-000046.md) | [18.6](/filings/0001792044-26-000041.md) | [15.7](/filings/0001792044-26-000041.md) | [15.6](/filings/0001792044-26-000041.md) | [15.2](/filings/0001792044-25-000046.md) | [14.7](/filings/0001792044-26-000041.md) | [14.7](/filings/0001792044-26-000041.md) | [14.3](/filings/0001792044-26-000041.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [835 d](/filings/0001792044-24-000033.md) | [569 d](/filings/0001792044-26-000013.md) | [615](/filings/0001792044-25-000018.md) | [379 d](/filings/0001792044-25-000033.md) | [827 d](/filings/0001792044-25-000046.md) | [483 d](/filings/0001792044-26-000013.md) | [536](/filings/0001792044-26-000029.md) | [220 d](/filings/0001792044-26-000041.md) | [745 d](/filings/0001792044-25-000046.md) | [816 d](/filings/0001792044-26-000013.md) | [388](/filings/0001792044-26-000029.md) | [382 d](/filings/0001792044-26-000041.md) |
| Capital expenditure | $m | [95.9 d](/filings/0001792044-24-000033.md) | [166 d](/filings/0001792044-26-000013.md) | [49.8](/filings/0001792044-25-000018.md) | [58.8 d](/filings/0001792044-25-000033.md) | [77.0 d](/filings/0001792044-25-000046.md) | [140 d](/filings/0001792044-26-000013.md) | [42.6](/filings/0001792044-26-000029.md) | [52.9 d](/filings/0001792044-26-000041.md) | [86.8 d](/filings/0001792044-25-000046.md) | [197 d](/filings/0001792044-26-000013.md) | [39.9](/filings/0001792044-26-000029.md) | [52.8 d](/filings/0001792044-26-000041.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001792044-24-000033.md) | [0.0 d](/filings/0001792044-26-000013.md) | [250](/filings/0001792044-25-000018.md) | [0.0 d](/filings/0001792044-25-000033.md) | [0.0 d](/filings/0001792044-25-000046.md) | [0.0 d](/filings/0001792044-26-000013.md) | [175](/filings/0001792044-26-000029.md) | [175](/filings/0001792044-26-000041.md) | [67.9](/filings/0001792044-25-000046.md) | [85.1 d](/filings/0001792044-26-000013.md) | [0.0](/filings/0001792044-26-000029.md) | [150 d](/filings/0001792044-26-000041.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,218](/filings/0001792044-22-000036.md) | [1,206](/filings/0001792044-24-000017.md) | [1,204](/filings/0001792044-24-000025.md) | [1,208](/filings/0001792044-24-000033.md) | [1,210](/filings/0001792044-25-000018.md) | [1,191](/filings/0001792044-25-000033.md) | [1,200](/filings/0001792044-25-000046.md) | [1,192](/filings/0001792044-26-000029.md) | [1,173](/filings/0001792044-26-000041.md) | [1,165](/filings/0001792044-25-000046.md) | [1,175](/filings/0001792044-26-000029.md) | [1,163](/filings/0001792044-26-000041.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,148,590,864 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001792044-26-000041.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.